Loading
A phase 2 trial of Antineoplastons in Brain and spinal cord tumours, run by Burzynski Research Institute, completed.
Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors is a phase 2 interventional study registered as NCT00003475 by Burzynski Research Institute, with 40 participants recorded, started 1996-02 and reaching its primary completion in 2011-05. Interventions recorded: Antineoplaston therapy (Atengenal + Astugenal). Conditions recorded: Malignant Brain Tumors.
Linked to the technology Antineoplastons because the registry's title names it ("antineoplastons") and Brain and spinal cord tumours among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Antineoplastons (Burzynski clinic) and the tag pipeline.
Shares Antineoplastons (Burzynski clinic) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/